Home page | Servier US
Servier is a leader in oncology and is building up its neurology business. We are dedicated to addressing rare diseases and patient populations with unmet needs.
Servier is a pharma company governed by a non-profit foundation
Welcome to the Servier website. Use the search field to explore our articles and resources. News 21.11.2025
Laboratoires Servier - Wikipedia
Servier Laboratories (French: Laboratoires Servier, often abbreviated to Servier) is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France …
Our group - Servier ME – a global pharmaceutical group governed by …
Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable …
Newsroom | Servier - News Releases
Servier Announces Positive Findings from Longer-Term Analysis of the Phase 3 INDIGO Trial Showing Continued Durable Treatment Effect of VORANIGO® (vorasidenib) Published in The Lancet Oncology
Insilico Medicine Announce US$888 Million Multi-Year Collaboration …
4 days ago · Insilico Medicine achieved an R&D collaboration with Servier valued at up to US$888 million, focused on discovering and developing innovative oncology...
MyServier | Servier's resources hub for healthcare professionals
MyServier is Servier’s resources hub for healthcare professionals, offering access to scientific resources, tools, and specialized content. Available across multiple countries, it supports healthcare …
Servier and Insilico sign an $888 million AI oncology discovery deal
3 days ago · On January 4, the French pharma group Servier and the AI drug discovery Insilico Medicine announced a collaboration worth up to $888 million. Insilico will receive up to $32 million …
Insilico pens potential $888M cancer R&D pact with Servier
4 days ago · Right on the heels of its IPO, Insilico Medicine is starting the year with an oncology discovery and development pact with French pharma Servier. The artificial intelligence biotech could …
Servier taps Insilico’s AI platform for early cancer R&D
3 days ago · Servier partners with Insilico Medicine in AI-driven cancer drug discovery deal worth up to $888M; Insilico to use Pharma.AI platform and receive $32M upfront.